21Jul 2023
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials

Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials

The study indicated PPI usage could reduce the effectiveness of abiraterone acetate plus prednisone (AAP) in treating metastatic prostate cancer, likely due to gut microbiota modifications. A study investigated whether PPI use impacted survival in metastatic prostate cancer patients treated with androgen deprivation therapy (ADT) and AAP. Results showed that in patients receiving AAP, PPI users experienced worse overall survival and progression-free survival compared to non-users.

  • #urology

Like

Save

Share